CABALETTA BIO INC (CABA) Stock News
NASDAQ:CABA - Nasdaq - US12674W1099 - Common Stock - Currency: USD
CABA Latest News, Press Relases and Analysis
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Top movers analysis in the middle of the day on 2025-06-11: top gainers and losers in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Which stocks are gapping on Wednesday?
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.
Cabaletta Bio Announces Pricing of Public Offering of Securities
Cabaletta Bio Announces Pricing of Public Offering of Securities
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company...
Cabaletta Bio Announces Proposed Public Offering of Securities
Cabaletta Bio Announces Proposed Public Offering of Securities
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering...
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
Cabaletta Bio Stock Surges To 2-Month High On Autoimmune Therapy Progress; Retail’s Pleased
The company announced the addition of two subtype-specific cohorts to its RESET-Myositis trial and received RMAT designation from the FDA for rese-cel.
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
– Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial – – RMAT designation granted for rese-cel in...
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across...
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and...
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and...
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
PHILADELPHIA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and...